Osimertinib (Osi) plus necitumumab (Neci) in EGFR-mutant NSCLC: An ETCTN California cancer consortium phase I study.
Jonathan W. Riess(University of California Davis Medical Center), David R. Gandara(University of California, Davis), Marianna Koczywas(City Of Hope National Medical Center), Jill Kolesar(University of Kentucky), Heather A. Wakelee(Palo Alto Institute), Geoffrey R. Oxnard(Foundation Medicine (United States)), Pasi A. Jänne(Harvard University), Karen L. Reckamp(Memorial Sloan Kettering Cancer Center), Sukhmani K. Padda(Stanford University), Cloud P. Paweletz(Massachusetts General Hospital), Susan Groshen(USC Norris Comprehensive Cancer Center), Zofia Piotrowska(Global Cancer Institute), Primo N. Lara(UC Davis Comprehensive Cancer Center), Edward M. Newman(City of Hope), Jeffrey A. Moscow(National Cancer Institute), Christie J. Lau(Dana-Farber Cancer Institute), Lynette M. Sholl(Brigham and Women's Hospital), Philip C. Mack(UC Davis Comprehensive Cancer Center)
Cited by 18
Related Papers
<i>EGFR</i> Mutations in Lung Cancer: Correlation with Clinical Response to Gefitinib Therapy
|Science|2004|9.4k
Atezolizumab versus docetaxel in patients with previously treated non-small-cell lung cancer (OAK): a phase 3, open-label, multicentre randomised controlled trial
|The Lancet|2016|4.8k
Anaplastic Lymphoma Kinase Inhibition in Non–Small-Cell Lung Cancer
|New England Journal of Medicine|2010|4.5k
<i>MET</i> Amplification Leads to Gefitinib Resistance in Lung Cancer by Activating ERBB3 Signaling
|Science|2007|4.5k
The landscape of somatic copy-number alteration across human cancers
|Nature|2010|4.1k